Journal Article

STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation

Li, Wen-Hao, Hu, Hong-Guo, Zhao, Yu-Fen, Li, Yan-Mei, He, Pei-Yang, Zhang, Bo-Dou, Wu, Jun-Jun, Zhao, Lang

2022

Overview

Immunostimulatory therapies based on pattern recognition receptors (PRRs) have emerged as an effective approach in the fight against cancer, with the ability to recruit tumor-specific lymphocytes in a low-immunogenicity tumor environment. The agonist cyclic dinucleotides (CDNs) of the stimulator of interferon gene (STING) are a group of very promising anticancer molecules that increase tumor immunogenicity by activating innate immunity. However, the tumor immune efficacy of CDNs is limited by several factors, including relatively narrow cytokine production, inefficient delivery to STING, and rapid clearance. In addition, a single adjuvant molecule is unable to elicit a broad cytokine response and thus cannot further amplify the anticancer effect. To address this problem, two or more agonist molecules are often used together to synergistically enhance immune efficacy. In this work, we found that a combination of the STING agonist CDG SF and the Toll-like receptor 7/8 (TLR7/8) agonist 522 produced a broader cytokine response. Subsequently, we developed multicomponent nanovaccines (MCNVs) consisting of a PC7A polymer as a nanocarrier encapsulating the antigen OVA and adjuvant molecules. These MCNVs activate bone marrow-derived dendritic cells (BMDCs) to produce multiple proinflammatory factors that promote antigen cross-presentation to stimulate specific antitumor T-cell responses. In in vivo experiments, we observed that MCNVs triggered a strong T-cell response in tumor-infiltrating lymphocytes, resulting in significant tumor regression and, notably, a 100% survival rate in mice through 25 days without other partnering therapies. These data suggest that our nanovaccines have great potential to advance cancer immunotherapy with increased durability and potency.

• Publisher: Tsinghua University Press
• Subject: Agonists / Anticancer properties / Antigen presentation / Antigens / Antitumor activity / Atomic/Molecular Structure and Spectra / Biomedicine / Biotechnology / Bone marrow / Cancer / Cancer immunotherapy / Chemistry and Materials Science / Condensed Matter Physics / Cytokines / Dendritic cells / Immune clearance / Immunogenicity / Immunostimulation / Immunotherapy / Inflammation / Innate immunity / Interferon / Lymphocytes / Lymphocytes T / Materials Science / Nanotechnology / Pattern recognition / Pattern recognition receptors / Polymers / Research Article / Stimulators / TLR7 protein / Toll-like receptors / Tumor-infiltrating lymphocytes / Tumors